Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners
Roanna Reese is a Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners, focusing on biotechnology equity research and analysis. She covers companies including Lantheus and Shine, with a depth of insight into radiopharmaceuticals and diagnostics, participating in earnings calls and market assessment. Reese has risen through the ranks within the firm and is recognized for deep sector specialization, though specific published data on her investment success rates or ranking metrics are not publicly available. She holds professional credentials required for senior analyst roles in equity research, including FINRA registration and securities licenses, and is noted for her analytical expertise on both corporate and investor-facing platforms.
Roanna Reese inquired about the strategies driving PYLARIFY and Neuraceq to the higher end of guidance, asking for elaboration on current traction and how these strategies might extend into 2026.
CEO Brian Markison highlighted PYLARIFY's market stabilization, customer returns after trialing alternatives, and Neuraceq's expansion and availability as key drivers. CFO Bob Marshall added that the focus remains on executing the existing strategy in a competitive market.
Roanna Reese asked about the factors contributing to Polarify and NeuroSeq trending towards the higher end of guidance, inquiring about the specific strategies gaining traction and their potential continuation into 2026.
Brian Markison, CEO, attributed Polarify's performance to market stabilization, customer returns after trialing alternatives, and effective execution. For NeuroSeq, he highlighted expansion and increased availability as key drivers. Bob Marshall, CFO, added that current visibility supports executing the existing strategy, acknowledging the competitive market.
Performance on expert-authored financial analysis tasks